KDEV Karolinska Development AB

Change of number of shares and votes in KDventures AB

Change of number of shares and votes in KDventures AB

STOCKHOLM, SWEDEN – February 27, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that the number of shares and votes has changed during February 2026 as a result of the rights issue resolved by the Board of Directors on December 1, 2025 and approved at the Extraordinary General Meeting on January 8, 2026 and the directed issue of shares to guarantors as compensation for guarantee commitments in connection with the rights issue resolved by the Board of directors on February 12, 2026.

Today, the last trading day of the month, there are 659,528,128 shares, representing a total of 682,525,477 votes outstanding in the company, distributed among 2,555,261 shares of series A (with 25,552,610 votes) and 656,972,867 shares of series B (with 656,972,867 votes).

For further information, please contact:

Viktor Drvota, CEO, KDventures AB

Phone: 2, e-mail:

Johan Dighed, General Counsel and Deputy CEO, KDventures AB

Phone: +46 70 207 48 26, e-mail:

This information is information that KDventures AB (publ) (Nasdaq Stockholm: KDV) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CET on February 27, 2026.

About KDventures AB

KDventures AB (Nasdaq Stockholm: KDV) is a Nordic investment company specialized in life sciences. The company identifies and invests in innovative pharmaceutical projects and medical technology products originating from leading research institutions in the Nordic region. Through a diversified portfolio across various stages of development, professional due diligence, and active board engagement, KDventures creates value from early research to commercialization. The company offers investors exposure to both listed and private life science projects with significant value growth potential.

For more information, please visit -ventures.com.

Attachment



EN
27/02/2026

Underlying

KDEVKarolinska Development AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Karolinska Development AB

 PRESS RELEASE
Free
KDEV Karolinska Deve...

KDventures announces that Organon has discontinued the development of ...

KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos’ drug candidate for PCOS STOCKHOLM, Sweden, March 3, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome (PCOS) that was part of the acquisition of the portfolio company Forendo. Thus, the development of both drug candidates included in the acquisition has been discontinued. KDventures will therefore write off its entire remaining book value of the agreement on poten...

March 3, 2026 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

KDventures meddelar att Organon har avbrutit utvecklingen av det tidig...

KDventures meddelar att Organon har avbrutit utvecklingen av det tidigare portföljbolaget Forendos läkemedelskandidat mot PCOS STOCKHOLM, 3 mars 2026. KDventures AB (publ) (Nasdaq Stockholm: KDV) meddelar idag att Organon har avbrutit utvecklingen av en preklinisk läkemedelskandidat mot polycystiskt ovariesyndrom (PCOS) som ingick i förvärvet av portföljbolaget Forendo. Därmed har utvecklingen av båda de läkemedelskandidater som ingick i förvärvet upphört. Till följd av detta kommer KDventures att skriva av hela sitt kvarvarande bokförda värde av det avtal om potentiella tillägsköpeskilling...

March 3, 2026 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Change of number of shares and votes in KDventures AB

Change of number of shares and votes in KDventures AB STOCKHOLM, SWEDEN – February 27, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that the number of shares and votes has changed during February 2026 as a result of the rights issue resolved by the Board of Directors on December 1, 2025 and approved at the Extraordinary General Meeting on January 8, 2026 and the directed issue of shares to guarantors as compensation for guarantee commitments in connection with the rights issue resolved by the Board of directors on February 12, 2026. Today, the last trading day of the month, ...

February 27, 2026 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Ändring av antal aktier och röster i KDventures AB

Ändring av antal aktier och röster i KDventures AB STOCKHOLM, SVERIGE den 27 februari 2026. KDventures AB (Nasdaq Stockholm: KDV) meddelar idag att antalet aktier och röster har ändrats under februari 2026 till följd av företrädesemissionen som beslutades av styrelsen den 1 december 2025 och godkändes på extra bolagsstämma den 8 januari 2026 samt den riktade nyemissionen av aktier till garanter för erläggande av garantiersättning i samband med företrädesemissionen som beslutades av styrelsen den 12 februari 2026. Idag, den sista handelsdagen i månaden, uppgår antalet aktier i bolaget till ...

February 27, 2026 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

KDventures’s portfolio company SVF Vaccines announces that the intende...

KDventures’s portfolio company SVF Vaccines announces that the intended merger with Novakand will not be carried out following negative decision from Nasdaq STOCKHOLM, Sweden, February 24, 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that the planned reversed acquisition of the portfolio company SVF Vaccines by Novakand Pharma will not be completed, following Nasdaq’s rejection of an application for continued listing of the combined entity. On February 6, 2026, it was announced that KDventures and the other shareholders of SVF Vaccines had entered into an acquisition agreement wit...

February 24, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch